We are pleased to announce that Ria de Haas has been appointed as the new Chief Executive Officer (CEO) of FSHD Europe. Having previously served as project manager, Ria is now stepping into this leadership role to help guide the organization forward.
This marks an important step in FSHD Europe’s growth, especially with ongoing advancements in drug development and initiatives like Project Mercury. Our mission remains clear—to unite and amplify the voices of FSHD patients and their families across Europe.